In 2023, the death rate from asthma in the United States was .8 per 100,000 population. This statistic represents the rate of death with asthma as the underlying cause in the United States from 2018 to 2023.

In 2023, the death rate for asthma in the United States was 0.7 for the male population and .9 for the female population. This statistic represents the rate of deaths with asthma as the underlying cause in the United States from 2018 to 2023, sorted by gender.

Around 7.7% of Americans have asthma, including 20.2 million adults and 4.6 million children. This study examines asthma mortality trends and disparities across U.S. demographic and geographic groups from 1999 to 2020. A retrospective analysis was conducted using the CDC WONDER database to examine asthma-related deaths in the U.S. from 1999 to 2020. Age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 were calculated. Trends and annual percent changes (APCs) were assessed overall and stratified by sex, race, region, and age. From 1999 to 2020, the U.S. recorded 221 161 asthma-related deaths (AAMR: 3.07), mostly in medical facilities. Mortality declined from 1999 to 2018 (APC: −1.53%) but surged from 2018 to 2020 (APC: 28.63%). Females, NH Blacks, and NH American Indians had the highest mortality rates. Older adults (≥65) had the greatest burden, with younger groups showing notable increases post-2018. Rural areas and the West reported slightly higher rates than urban and other regions. Hawaii and the District of Columbia had the highest AAMRs, while Florida and Nevada had the lowest. Asthma-related mortality in the U.S. declined until 2018 but sharply increased from 2018 to 2020, with rises across all demographic groups, regions, and settings. Females, NH Blacks, and older adults consistently had higher mortality rates, while younger age groups showed recent alarming increases. Targeted interventions are urgently needed to address inequities and recent mortality surges.

In 2016-2018, around 19 percent of children in the South with current asthma had an asthma attack in the past 12 months. This statistic illustrates the prevalence of asthma attacks in the past 12 months among children with current asthma in the United States from 2016 to 2018, by region.

The MarketScan health claims database is a compilation of nearly 110 million patient records with information from more than 100 private insurance carriers and large self-insuring companies. Public forms of insurance (i.e., Medicare and Medicaid) are not included, nor are small (< 100 employees) or medium (1000 employees). We excluded the relatively few (n=6735) individuals over 65 years of age because Medicare is the primary insurance of U.S. adults over 65. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Gray, C., D. Lobdell, K. Rappazzo, Y. Jian, J. Jagai, L. Messer, A. Patel, S. Deflorio-Barker, C. Lyttle, J. Solway, and A. Rzhetsky. Associations between environmental quality and adult asthma prevalence in medical claims data. ENVIRONMENTAL RESEARCH. Elsevier B.V., Amsterdam, NETHERLANDS, 166: 529-536, (2018).

BackgroundThe lymphocyte-to-high-density lipoprotein ratio (LHR), a novel biomarker reflecting systemic inflammation and immune status, has been widely studied in various diseases. However, its association with mortality risk among asthma patients remains unexplored.MethodsThis study utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999–2018, including 5,323 adult asthma patients. Mortality outcomes were ascertained through linkage with the National Death Index (NDI) up to December 31, 2019. Cox proportional hazards models and Fine-Gray competing risk models were employed to examine the association between LHR and mortality risks. Dose–response relationships were assessed using restricted cubic spline analyses.ResultsOver a mean follow-up period of 106.95 months, 724 all-cause deaths (13.6%) were recorded. After multivariable adjustment, a one-unit increase in log-transformed LHR was associated with reduced risks of mortality: 18% for all-cause (HR = 0.82, 95% CI: 0.74–0.91), 21% for cardiovascular disease (CVD) (HR = 0.79, 95% CI: 0.65–0.96), and 41% for chronic lower respiratory disease (CLRD) (HR = 0.59, 95% CI: 0.45–0.77). Restricted cubic spline analyses showed an L-shaped association of LHR with all-cause and CLRD mortality, with inflection points at 1.78 and 1.52, respectively. For CVD mortality, a linear association was observed. Competing risk models further confirmed the association of LHR with reduced CLRD mortality (SHR = 0.64, 95% CI: 0.46–0.88), while the association with CVD mortality was no longer significant (SHR = 0.85, 95% CI: 0.70–1.03).ConclusionLHR is nonlinearly associated with all-cause and CLRD mortality and shows a significant inverse association with CLRD mortality risk. These findings were further validated using competing risk models, highlighting the robustness of the results.

The aim of this project is to determine appropriate models for estimating and projecting the prevalence and disease burden of asthma.

The highest prevalence of current asthma among U.S. children was reported in Connecticut, where 10.6 percent of all children were estimated to currently suffer from asthma. This statistic represents the prevalence of current asthma among children in the United States in 2022, by state.

This data shows healthcare utilization for asthma by Allegheny County residents 18 years of age and younger. It counts asthma-related visits to the Emergency Department (ED), hospitalizations, urgent care visits, and asthma controller medication dispensing events. The asthma data was compiled as part of the Allegheny County Health Department’s Asthma Task Force, which was established in 2018. The Task Force was formed to identify strategies to decrease asthma inpatient and emergency utilization among children (ages 0-18), with special focus on children receiving services funded by Medicaid. Data is being used to improve the understanding of asthma in Allegheny County, and inform the recommended actions of the task force. Data will also be used to evaluate progress toward the goal of reducing asthma-related hospitalization and ED visits. Regarding this data, asthma is defined using the International Classification of Diseases, Tenth Revision (IDC-10) classification system code J45.xxx. The ICD-10 system is used to classify diagnoses, symptoms, and procedures in the U.S. healthcare system. Children seeking care for an asthma-related claim in 2017 are represented in the data. Data is compiled by the Health Department from medical claims submitted to three health plans (UPMC, Gateway Health, and Highmark). Claims may also come from people enrolled in Medicaid plans managed by these insurers. The Health Department estimates that 74% of the County’s population aged 0-18 is represented in the data. Users should be cautious of using administrative claims data as a measure of disease prevalence and interpreting trends over time. Missing from the data are the uninsured, members in participating plans enrolled for less than 90 continuous days in 2017, children with an asthma-related condition that did not file a claim in 2017, and children participating in plans managed by insurers that did not share data with the Health Department. Data users should also be aware that diagnoses may also be subject to misclassification, and that children with an asthmatic condition may not be diagnosed. It is also possible that some children may be counted more than once in the data if they are enrolled in a plan by more than one participating insurer and file a claim on each policy in the same calendar year.

Table contains estimated percentage of adults ages 18 years and older who report ever being diagnosed with asthma by a healthcare provider. Data are at zip code level. Data are downloaded from the AskCHIS Neighborhood Edition and are not direct estimates. For more information on the methodology used to calculate estimates, please visit healthpolicy.ucla.edu. Data for zip codes 94305 and 95053 are not available. Source: California Health Interview Survey, AskCHIS Neighborhood Edition, 2018 CHIS data. Exported on June 1, 2022.METADATA:notes (String): Lists table title, notes, sourceszip_code (Numeric): Geography IDestimate (Numeric): Estimate of adults with asthmaunit (String): Unit used for the estimate (Percent)CI (Numeric): 95% confidence interval for the estimate

BackgroundThe advanced lung cancer inflammation index (ALI), which reflects both inflammation and nutritional status, has an uncertain role in predicting outcomes for asthma patients. This study aimed to evaluate the association between ALI and mortality from all causes, as well as specific causes including cardiovascular disease (CVD) and cancer-related mortality, among individuals with asthma.MethodsWe analyzed data from 4,829 asthma patients who participated in the U.S. National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Cox proportional hazards models were used to assess the relationship between ALI and both all-cause and cause-specific mortality, adjusting for demographic and clinical variables. Additionally, restricted cubic spline models were applied to explore potential nonlinear trends, while segmented Cox models were used to identify threshold effects. A competing risk model further examined the independent association of ALI with CVD mortality.ResultsOver a median follow-up of 7.83 years, a total of 582 deaths from all causes, 151 cardiovascular-related deaths, and 125 cancer-related deaths were recorded. An L-shaped association was observed between ALI and both all-cause and CVD mortality, with thresholds identified at 82.02 for all-cause mortality and 58.40 for CVD mortality. Compared to the lowest quartile of ALI (Q1), patients in the highest quartile (Q4) had a 49% lower risk of all-cause mortality (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.40–0.66) and a 51% reduction in CVD mortality (HR 0.49, 95% CI 0.29–0.83). This protective effect was further confirmed by the competing risk model. No significant association between ALI and cancer mortality was observed (HR 1.01, 95% CI 0.98–1.03).ConclusionALI was significantly and inversely associated with all-cause and CVD mortality in asthma patients, particularly when ALI values were below 82.02 and 58.40, respectively, where the risk of mortality was substantially lower. These findings suggest that ALI may have clinical utility in assessing prognosis for asthma patients, especially in terms of cardiovascular risk evaluation.

Asthma & COPD Market Outlook

According to our latest research, the global Asthma & COPD market size reached USD 40.8 billion in 2024, with a robust growth trajectory supported by a compound annual growth rate (CAGR) of 5.7% from 2025 to 2033. The market is projected to expand to USD 67.6 billion by 2033, driven by factors such as the rising prevalence of respiratory diseases, advancements in drug delivery technologies, and increasing awareness about early diagnosis and management of asthma and chronic obstructive pulmonary disease (COPD). As per our latest research, the market’s expansion is also attributed to the growing geriatric population and escalating environmental pollution levels worldwide, which are recognized as significant contributors to respiratory disorders.

One of the primary growth factors for the Asthma & COPD market is the increasing global burden of respiratory diseases. The prevalence of asthma and COPD is surging due to various factors such as urbanization, exposure to air pollutants, tobacco smoke, and occupational hazards. The World Health Organization (WHO) estimates that over 262 million people suffer from asthma, while COPD remains the third leading cause of death globally. This escalating patient pool necessitates effective management strategies, thereby propelling demand for inhalers, nebulizers, drugs, and oxygen therapy devices. Moreover, the adoption of combination therapies and the introduction of novel biologics have significantly improved patient outcomes, further supporting market growth. Healthcare systems across developed and emerging economies are increasingly prioritizing respiratory health, leading to greater investments in research, diagnosis, and treatment infrastructure.

Technological advancements in drug delivery systems and therapeutic devices have revolutionized the Asthma & COPD market. The development of smart inhalers, portable nebulizers, and digital health solutions has enhanced the efficiency and convenience of disease management. These innovations enable real-time monitoring of patient adherence and symptom control, which is crucial for chronic disease management. Pharmaceutical companies are focusing on the formulation of long-acting bronchodilators, corticosteroids, and targeted biologics, offering better efficacy and reduced side effects. Additionally, the integration of artificial intelligence and telemedicine in respiratory care is transforming patient engagement, enabling remote consultations and personalized treatment plans. Such technological progress not only improves patient quality of life but also reduces healthcare costs associated with hospitalizations and exacerbations.

Another significant growth driver is the increasing awareness and proactive screening initiatives for asthma and COPD. Governments, non-profit organizations, and healthcare providers are conducting large-scale awareness campaigns to educate the public about the early signs and risk factors of respiratory diseases. Early diagnosis is crucial for effective disease management and can substantially reduce the risk of severe complications. The expansion of healthcare access, especially in emerging markets, has facilitated timely diagnosis and intervention. Furthermore, reimbursement policies for respiratory therapies and drugs are becoming more favorable, encouraging patients to seek medical care and adhere to prescribed treatments. These collective efforts are fostering a supportive environment for the sustained growth of the Asthma & COPD market.

From a regional perspective, North America and Europe continue to dominate the Asthma & COPD market due to their advanced healthcare infrastructure, high disease awareness, and strong presence of leading pharmaceutical companies. The Asia Pacific region, however, is witnessing the fastest growth, driven by increasing urbanization, rising air pollution levels, and a large, underserved patient population. Countries like China and India are experiencing a surge in respiratory disease cases, prompting significant investments in healthcare infrastructure and respiratory care solutions. Latin America and the Middle East & Africa are also showing promising growth potential, supported by improving healthcare access and rising government initiatives aimed at combating respiratory diseases. The global landscape is thus characterized by both established markets with high adoption rates and emerging regions with substantial untapped opportunities.
</

Number and percentage of persons having been diagnosed with asthma, by age group and sex.

In 2022, around 8.2 percent of the U.S. population currently had asthma. Over the past couple decades, the share of the U.S. population with current asthma has fluctuated. The years 2010 and 2011 saw the highest prevalence rates, with 8.5 percent in both years.

Asthma Asthma is a complicated chronic illness that affects a person’s ability to breathe. Symptoms include shortness of breath, wheezing and coughing. Asthma is treatable through avoidance of triggers and through inhaled corticosteroids (an inhaler). Prescriptions of Albuterol, a commonly prescribed inhaler, have increased significantly in the United States. Fortunately, in recent years, the out-of-pocket costs of albuterol have decreased. Asthma among the states The prevalence of asthma in U.S. states varies, with Rhode Island, Maine, and New Hampshire reporting the highest current rates of asthma. However, despite having the highest prevalence rates, these states do not have the highest death rates due to asthma. As of 2021, Mississippi and Hawaii had the highest death rates from asthma in the United States. Among all U.S. residents, the prevalence of active asthma attacks within the past 12 months has decreased over the last few years.

In 2018, chronic asthma was more common in women than in men in Belgium. Indeed, in 2018, while 6.5 percent of adult women suffered from asthma, five percent of adult males were asthmatic. Since 2001, the prevalence of chronic asthma in the adult Belgian population increased.

Asthma prevalence is high among elite endurance athletes, but little is known about its prevalence among competitive recreational athletes. The aim of this study was to determine the prevalence of self-reported asthma and asthma medication use among competitive recreational endurance athletes, and their association with training. A web survey on asthma and medication was conducted among 38,603 adult participants of three Swedish endurance competitions (cross-country running, cross-country skiing, and swimming).

Purpose:

The aim of this cross-sectional study was to determine the prevalence among competitive recreational endurance athletes of self-reported physician-diagnosed asthma and asthma medication use and their association with training.

This dataset provides an estimate of the percentage of adult respondents ages 18+ who were ever diagnosed with asthma by a doctor by zip code as well as an estimate of the population ages 18+ residing in that zip code. The estimates covered are from the years 2013-2014. Information like this may be useful for studying asthma rates across zip codes of different demographics.

Spatial Extent: Los Angeles Spatial Unit: Zip Code Created: 2018 Updated: n/a Source: California Health Interview Survey Contact Telephone: 310-794-0909 Contact Email: dacchpr@ucla.edu Source Link: https://askchisne.ucla.edu/ask/_layouts/ne/dashboard.aspx#/API Source Link: https://www.arcgis.com/home/item.html?id=cabe5663e01948dfa4bc31922c2c791b

Adult respondents ages 18+ who were ever diagnosed with asthma by a doctor. Years covered are from 2013-2014 by zip code. Data taken from the California Health Interview Survey Neighborhood Edition (AskCHIS NE) (http://askchisne.ucla.edu/), downloaded February 2018. AskCHIS Neighborhood Edition is an online data dissemination and visualization platform that provides health estimates at sub-county geographic regions. Estimates are powered by data from The California Health Interview Survey (CHIS). CHIS is conducted by The UCLA Center for Health Policy Research, an affiliate of UCLA Fielding School of Public Health.Health estimates available in AskCHIS NE (Neighborhood Edition) are model-based small area estimates (SAEs).SAEs are not direct estimates (estimates produced directly from survey data, such as those provided through AskCHIS).CHIS data and analytic results are used extensively in California in policy development, service planning and research, and is recognized and valued nationally as a model population-based health survey.Before using estimates from AskCHIS NE, it is recommended that you read more about the methodology and data limitations at: http://healthpolicy.ucla.edu/Lists/AskCHIS%20NE%20Page%20Content/AllItems.aspx. You can go to http://askchisne.ucla.edu/ to create your own account.Produced by The California Health Interview Survey and The UCLA Center for Health Policy Research and compiled by the Los Angeles County Department of Public Health. "Field Name = Field Definition "Zipcode" = postal zip code in the City of Los Angeles “Percent” = estimated percentage of adult respondents ages 18+ who were ever diagnosed with asthma by a doctor"LowerCL" = the lower 95% confidence limit represents the lower margin of error that occurs with statistical sampling"UpperCL" = the upper 95% confidence limit represents the upper margin of error that occurs in statistical sampling "Population" = estimated population 18 and older (denominator) residing in the zip code Notes: 1) Zip codes are based on the Los Angeles Housing Department Zip Codes Within the City of Los Angeles map (https://media.metro.net/about_us/pla/images/lazipcodes.pdf).2) Zip codes that did not have data available (i.e., null values) are not included in the dataset; there are additional zip codes that fall within the City of Los Angeles.3) Zip code boundaries do not align with political boundaries. These data are best viewed with a City of Los Angeles political boundary file (i.e., City of Los Angeles jurisdiction boundary, City Council boundary, etc.) FAQS: 1. Which cycle of CHIS does AskCHIS Neighborhood Edition provide estimates for?All health estimates in this version of AskCHIS Neighborhood Edition are based on data from the 2013-2014 California Health Interview Survey. 2. Why do your population estimates differ from other sources like ACS? The population estimates in AskCHIS NE represent the CHIS 2013-2014 population sample, which excludes Californians living in group quarters (such as prisons, nursing homes, and dormitories). 3. Why isn't there data available for all ZIP codes in Los Angeles?While AskCHIS NE has data on all ZCTAs (Zip Code Tabulation Areas), two factors may influence our ability to display the estimates:A small population (under 15,000): currently, the application only shows estimates for geographic entities with populations above 15,000. If your ZCTA has a population below this threshold, the easiest way to obtain data is to combine it with a neighboring ZCTA and obtain a pooled estimate.A high coefficient of variation: high coefficients of variation denote statistical instability.

BackgroundChronic Obstructive Pulmonary Disease (COPD), mainly caused by cigarette smoking, is one of the leading causes of death in the United States (US) and frequent asthma attacks are often exacerbated by cigarette use. Electronic cigarettes (e-cigarettes) are often used to quit cigarette smoking. Prevalence of COPD, asthma, cigarette use, and e-cigarette use differs between racial/ethnic groups. The overall objective was to assess the associations between e-cigarette use and COPD and asthma and how race/ethnicity and cigarette smoking modifies these associations.MethodsData were retrieved from the 2016–2018 and 2020–2021 Behavioral Risk Factor Surveillance System datasets, a national annual health survey representing the US general adult population. Frequency and weighted percentages or means and standard deviations were obtained. Rao-Scott Chi-square test, two-sample t tests, and logistic regression were used to evaluate binary associations between current e-cigarette use and lifetime diagnosis of COPD and asthma. Multivariable analyses using logistic regression were conducted to assess associations between variables. Interaction effects between e-cigarette use and race/ethnicity were assessed and stratified analyses were performed as indicated. All multivariate analyses were stratified by cigarette smoking status.ResultsPrevalence of e-cigarette use was 5.1%, COPD was 6.7%, and asthma was 9.2%. Individuals who currently smoked cigarettes among all racial/ethnic groups, excluding non-Hispanic (NH) American Indian/Alaska Native individuals, were more likely to report current asthma if using e-cigarettes compared to non-use (p 

Background and objectiveSeveral studies suggest that air pollution, particularly PM2.5, increases morbidity and mortality, Emergency Department (ED) visits, and hospitalizations for acute respiratory and cardiovascular diseases. However, no prior study in Southeastern Asia (SEA) has examined the effects of air pollutants on ED visits and health outcomes. This study focused on the association of the Air Quality Index (AQI) of PM2.5 and other pollutants’ effects on ED visits, hospitalization, and unexpected deaths due to acute respiratory disease, acute coronary syndrome (ACS), acute heart failure (AHF), and stroke.MethodsWe conducted a retrospective study with daily data from ED visits between 2018 and 2019 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand. The AQI of air pollution data was collected from outdoor air quality from the Smoke Haze Integrated Research Unit and the Air Quality Index Visual Map. A distributed lag, non-linear and quasi-Poisson models were used to explore the relationship between air quality parameters and ED visits for each disease.Results3,540 ED visits were recorded during the study period. The mean daily AQI of PM2.5 was 89.0 ± 40.2. We observed associations between AQI of PM2.5 and the ED visits due to ACS on the following day (RR = 1.023, 95% confidence interval [CI]: 1.002–1.044) and two days after exposure (RR = 1.026, 95% CI: 1.005–1.047). Also, subgroup analysis revealed the association between AQI of PM2.5 and the ED visits due to pneumonia on the current day (RR = 1.071, 95% CI: 1.025–1.118) and on the following day after exposure (RR = 1.024, 95% CI: 1.003–1.046). AQI of PM2.5 associated with increased mortality resulted from ACS on lag day 3 (OR = 1.36, 95% CI: 1.08–1.73). The AQI of PM10 is also associated with increased ED visits due to COPD/asthma and increased hospitalization in AHF. In addition, the AQI of O3 and AQI of NO2 is associated with increased ICU admissions and mortality in AHF.ConclusionShort-term PM2.5 exposure escalates ED visits for ACS and pneumonia. PM10’s AQI associates with COPD/asthma ED visits and AHF hospitalizations. AQI of O3 and NO2’s link to increased ICU admissions and AHF mortality. Urgent action against air pollution is vital to safeguard public health.